Cabaletta

First Patients Receive Cabaletta Bio’s Rese-cel Produced Using Cellares’ Automated Cell Shuttle™ Platform

First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares’ Automated Cell Shuttle™ Platform Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.’s (“Cabaletta…

Read MoreFirst Patients Receive Cabaletta Bio’s Rese-cel Produced Using Cellares’ Automated Cell Shuttle™ Platform

VectorBuilder Launches High-Stability MuteFree™ AAV to Enhance Gene Therapy Manufacturing Reliability

VectorBuilder Introduces High-Stability MuteFree™ AAV to Improve Gene Therapy Manufacturing Reliability VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a high-stability AAV vector…

Read MoreVectorBuilder Launches High-Stability MuteFree™ AAV to Enhance Gene Therapy Manufacturing Reliability
ImmuVia

ImmuVia Chooses Quantori’s Q-Scientist Platform to Advance First-in-Class Cancer Therapy Development

ImmuVia Selects Quantori’s Q-Scientist Platform to Accelerate Development of First-in-Class Cancer Therapy ImmuVia Inc., a biotechnology company developing first-in-class therapies for solid tumors, today announced that it has selected Quantori, a…

Read MoreImmuVia Chooses Quantori’s Q-Scientist Platform to Advance First-in-Class Cancer Therapy Development

Obsidian Therapeutics and Galera Therapeutics Announce Merger Deal and $350 Million Private Placement Financing

Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor…

Read MoreObsidian Therapeutics and Galera Therapeutics Announce Merger Deal and $350 Million Private Placement Financing

Dyve Biosciences and Moffitt Cancer Center Highlight Encouraging Results for Novel Topical Therapy Targeting Tumor Acidity

Dyve Biosciences and Moffitt Cancer Center Report Promising Study Results for First-of-Its-Kind Topical Therapy Targeting Tumor Acidity Dyve Biosciences, in collaboration with Moffitt Cancer Center, today reported significant study results…

Read MoreDyve Biosciences and Moffitt Cancer Center Highlight Encouraging Results for Novel Topical Therapy Targeting Tumor Acidity